Plain-English translation of NCT03571373 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study that follows children who have recently been diagnosed with inflammatory bowel disease (IBD)—conditions like Crohn's disease or ulcerative colitis. Researchers will collect information about your diagnosis, the treatments you receive, and how you respond to those treatments over time. The goal is to learn which treatment strategies work best for different patients and to catch any serious side effects early.
Doctors want to better understand what treatments work safest and most effectively for children with IBD, especially when the disease is newly diagnosed. By tracking many patients and their outcomes, researchers can identify warning signs of rare complications and improve care for all children with these conditions.
You likely qualify if…
You likely don't qualify if…
If you join the main study group, your doctors will share your medical records and treatment information with the research team. If you have rare complications from IBD, you may also be included in a separate safety registry to help doctors understand and prevent these serious problems. This is an observational study, meaning researchers watch and collect data—they are not testing a new drug, but rather learning from the treatments you already receive from your doctors.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Netherlands
United Kingdom
Sponsor
PIBD-Net
Collaborators
European Commission
Enrollment target
~1,500 participants
Started
January 2017
Primary completion
December 2027
Age range
0 Years – 19 Years
Last updated on clinicaltrials.gov in August 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Frank Ruemmele, MD, PhD
Erasmus Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.